NCT06381050View on ClinicalTrials.gov

The Clinical Study of SHR-7631 for Injection in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 24, 2024

Primary Completion Date

March 21, 2025

Study Completion Date

March 21, 2025

Conditions

Advanced Solid Tumors

Interventions

DRUG

SHR-7631

The total dosage of SHR-7631 was calculated according to the weight weighing results of the subjects before each administration, and was administered by intravenous drip.

Trial Locations (2)

100142

Peking University Cancer Hospital, Beijing

510062

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors

lead

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

INDUSTRY

NCT06381050 - The Clinical Study of SHR-7631 for Injection in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter